Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017
May 4, 2017

Message from the CEO

IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following clinical Phase lll study of IBP-9414. As previously stated, a Phase lll study will require additional capital. IBT is actively working with several potential financing possibilities and is seeking partners who can contribute resources for the continuing development program. We expect to gain improved understanding how agencies and experts view our new project IBP-1016, we also expect to receive our Phase II results of IBP-9414 (NCT02472769), and plan to apply for the main marketplace, Nasdaq Stockholm.

Staffan Strömberg

Financial summary
SEK 000's 2017
Total comprehensive income 117 162
Operating profit/loss -8 563 -5 103 -38 090
Result after tax -8 563 -5 165 -38 106
Total assets  100 925  55 593  110 109
Cash flow for the period -9 113 -6 782  49 375
Cash  84 673  37 629  93 786
Earnings per share, weighted average, before and after dilution (SEK) -1,56 -2,82 -8,42
Equity per share (SEK) 17,56 26,73 19,12
Equity ratio (%) 96% 91% 96%

Significant events during the first quarter 2017

  • In January 2017, all 120 patients were included in the Company's phase ll clinical trial in IBP-9414 (NCT02472769)
  • IBT's series B shares were listed on Nasdaq First North Premier on March 14

Significant events after the reporting period

  • No significant events have occurred after the reporting period

 Infant Bacterial Therapeutics AB (publ) Interim Report  is now available on the companies website

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.
 IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
 IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

For additional information please contact
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on May 4, 2017.

IBT Q1 2017 English
PR 20170504 Q1 ENG

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infant Bacterial Therapeutics AB via Globenewswire